TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4016519

Group type: EXPERIMENTAL
Intervention: Coban bandaging for 3 days
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Coban bandaging for 6 weeks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Crepe bandaging for 6 weeks
Number of subjects: 154
Study: 29102263

Group type: EXPERIMENTAL
Intervention: Re-irradiation
Number of subjects: 847
Study: 27267268

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20μg once daily
Number of subjects: 437
Study: 24272966

Group type: EXPERIMENTAL
Intervention: D-ribose 2.5g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-ribose 5.0g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-ribose 10.0g
Number of subjects: 12

Group type: COMPARATOR
Intervention: D-ribose 10.0g with high fat meal (HF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: D-ribose 10.0g with high carbohydrate meal (HC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-ribose (all doses)
Number of subjects: 12
Study: 22559322

Group type: EXPERIMENTAL
Intervention: Patient-tailored exercise intervention for participants with high exercise self-efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-tailored exercise intervention with group-based intervention for participants with low exercise self-efficacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular Dutch diabetes care (Control group)
Number of subjects: 0
Study: 20682569

Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1% nasal drops
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Control)
Number of subjects: 104
Study: 18078723

Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 50 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intranasal methamphetamine 0 mg (control)
Number of subjects: 11
Study: 16365618

Group type: EXPERIMENTAL
Intervention: Inpatient Geriatric Unit (GEMU)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Outpatient Geriatric Clinic (GEMC)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Usual Inpatient Care (UCIP)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Usual Outpatient Care (UCOP)
Number of subjects: 1388
Study: 11239552

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg depot) every 28 days for 8 weeks
Number of subjects: 358

Group type: COMPARATOR
Intervention: Sham depot every 28 days for 8 weeks
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg depot)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Sham depot
Number of subjects: 358
Study: 9727569

Group type: EXPERIMENTAL
Intervention: Immediate therapy (group A: ritonavir, zidovudine and lamivudine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Delayed therapy (group B: ritonavir supplemented by zidovudine and lamivudine on day 21)
Number of subjects: 29
Study: 7958383

Group type: EXPERIMENTAL
Intervention: Procaine penicillin G (4.8 mega units, intramuscularly), oral probenecid (1 g), and clavulanate-potentiated amoxycillin (375 mg tablet, orally)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Further assessment on day 7 for patients with remaining discharge
Number of subjects: 55
Study: 2903812

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31927647

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser (area A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm) (area C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined use of fractional CO2 laser and Q-switched Nd:YAG laser (area B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study: 29231133

Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib, melphalan, and prednisone
Number of subjects: 706

Group type: COMPARATOR
Intervention: Bortezomib, melphalan, and prednisone (control group)
Number of subjects: 706
Study: 27002662

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) including active stretching, ROM and pendulum exercises
Number of subjects: 41
Study: 25487477

Group type: EXPERIMENTAL
Intervention: Single shot bilateral intercostal block with levobupivacaine (L group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9 % saline (S group)
Number of subjects: 60
Study: 22502849

Group type: EXPERIMENTAL
Intervention: Internet-based motor, perceptual and cognitive training for 30 min each day for 20 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study: 19816834

Group type: EXPERIMENTAL
Intervention: Narrative exposure therapy (NET)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 32
Study: 18555862

Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RH)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Total hip arthroplasty (THA)
Number of subjects: 205
Study: 16024479

Group type: EXPERIMENTAL
Intervention: Intervention group received additional support from a social worker for goal setting, motivation, and planning for return to work.
Number of subjects: 184

Group type: COMPARATOR
Intervention: Reference group (control) did not receive additional support from a social worker.
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 184

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 184
Study: 12236631

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 10438552

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) plus standard medical treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study: 8526835

Group type: EXPERIMENTAL
Intervention: 7 days of absolute bed rest
Number of subjects: 5
Study: 2170921

Group type: EXPERIMENTAL
Intervention: Aconit
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 727631

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Iodoxouridine (IDU)
Number of subjects: 21
Study: 30143002

Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combined Physical And Cognitive Training (PACT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waitlist Group (WG)
Number of subjects: 93
Study: 27116462

Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo lubricant
Number of subjects: 80
Study: 25294621

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - supervised resistance training to arm and hip extensors on 3 days a week with additional 2 days a week of light walking
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual care group (UC) - participated in usual activities provided within their living facility
Number of subjects: 13
Study: 22367982

Group type: EXPERIMENTAL
Intervention: Activity scheduling
Number of subjects: 597
Study: 20586748

Group type: EXPERIMENTAL
Intervention: Intracapsular local anaesthesia with 20 ml ropivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-articular local anaesthesia with 20 ml ropivacaine 0.5%
Number of subjects: 60
Study: 17095133

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham acupuncture intervention
Number of subjects: 27
Study: 16321179

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7510

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 7510

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 7510

Group type: EXPERIMENTAL
Intervention: All types of reperfusion therapy
Number of subjects: 7510

Group type: EXPERIMENTAL
Intervention: Composite outcome (all-cause mortality, re-infarction, stroke within 7 days)
Number of subjects: 7510

Group type: EXPERIMENTAL
Intervention: All-cause mortality within 30 days
Number of subjects: 7510
Study: 11904788

Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg once daily
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg three times daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 10603633

Group type: EXPERIMENTAL
Intervention: Induced sputum (IS) technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 0
Study: 7725560

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound scanning (TRUS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 61
Study: 2047061

Group type: EXPERIMENTAL
Intervention: Intravaginal prostaglandin E2 (PGE2) gel (2.0 mg, twice-weekly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6996112

Group type: EXPERIMENTAL
Intervention: Iron supplementation during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No iron or intermittent iron supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron-treated mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (untreated mothers)
Number of subjects: 0
Study: 30355775

Group type: EXPERIMENTAL
Intervention: Lanreotide depot/autogel 120 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 27762088

Group type: EXPERIMENTAL
Intervention: BBT plus 50 mg ipragliflozin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BBT plus 50 mg ipragliflozin and 20 mg teneligliptin
Number of subjects: 58

Group type: COMPARATOR
Intervention: BBT alone
Number of subjects: 58
Study: 25913905

Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 67
Study: 24359311

Group type: EXPERIMENTAL
Intervention: LigaSure seal alone (Group 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LigaSure seal with oversewing (Group 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staple line intact (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staple line oversewn (Group 2)
Number of subjects: 0
Study: 22844543

Group type: EXPERIMENTAL
Intervention: Liquefied carbohydrate (CL, peach blended in 500 ml water + 250 ml water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solid carbohydrate (CS, whole peaches + 750 ml water)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Liquefied carbohydrate (CL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solid carbohydrate (CS)
Number of subjects: 10
Study: 19232755

Group type: EXPERIMENTAL
Intervention: Amlodipine-based treatment and atorvastatin 10 mg
Number of subjects: 19342

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 19342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19342
Study: 17465453

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15272513

Group type: EXPERIMENTAL
Intervention: 1 ml ropivacaine 7.5 mg/ml
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 ml ropivacaine 7.5 mg/ml
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1 ml ropivacaine 7.5 mg/ml (nerve block)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2 ml ropivacaine 7.5 mg/ml (nerve block)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ropivacaine (both dosages)
Number of subjects: 41
Study: 12578906

Group type: EXPERIMENTAL
Intervention: Dietary intervention with n‐3 polyunsaturated fatty acids (PUFAs), advised to decrease consumption of fats/oils and n‐6 PUFAs, and increase intake of n‐3 PUFAs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group advised to reduce intake of fats/oils as a whole.
Number of subjects: 0
Study: 9652426

Group type: EXPERIMENTAL
Intervention: Zidovudine, 1000 mg daily for 24 weeks
Number of subjects: 28
Study: 1443451

Group type: EXPERIMENTAL
Intervention: Budesonide, 100 micrograms in each nostril morning and evening for 4 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Astemizole, one 10-mg tablet each morning for 4 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 69

Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 69
Study: 2935051

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg every 6 hr
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg every 12 hr
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no other treatment)
Number of subjects: 8
Study: 30789775

Group type: EXPERIMENTAL
Intervention: CommunityRx intervention (usual care + personalized list of community resources)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (usual care only)
Number of subjects: 411
Study: 29228392

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with no RBV for the first 2 weeks followed by weight-based dosing thereafter (Arm A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with weight-based RBV for all 12 weeks (Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with low-dose RBV (600 mg) once daily for all 12 weeks (Arm C)
Number of subjects: 0
Study: 26975476

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis
Number of subjects: 3527

Group type: COMPARATOR
Intervention: No thromboprophylaxis
Number of subjects: 3527
Study: 24618327

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23106321

Group type: EXPERIMENTAL
Intervention: Occlusive polypropylene clips applied to the breech
Number of subjects: 32028
Study: 20061962

Group type: EXPERIMENTAL
Intervention: Patient-Rated Troubling Symptoms for Depression (PaRTS-D) instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PaRTS-D total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PaRTS-D global total score
Number of subjects: 0
Study: 17611081

Group type: EXPERIMENTAL
Intervention: GHB plus NTX
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 55

Group type: COMPARATOR
Intervention: NTX
Number of subjects: 55
Study: 16297747

Group type: EXPERIMENTAL
Intervention: 1‐ to 1.5‐microg/kg dose of fentanyl
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11977539

Group type: EXPERIMENTAL
Intervention: CGS 20267 0.5 mg once daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CGS 20267 1.0 mg once daily
Number of subjects: 64
Study: 9606816

Group type: EXPERIMENTAL
Intervention: Preadmission social work intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study: 7487186

Group type: EXPERIMENTAL
Intervention: Extracorporeal piezoelectric lithotripsy (EPL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 70
Study: 2406330

Group type: EXPERIMENTAL
Intervention: Calcitonin (415 pmol i.v. bolus injection followed by a 90‐min infusion to reach an overall dose of 62.25 pmol/kg body mass)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 11
Study: 6988522

Group type: EXPERIMENTAL
Intervention: Gentamicin (normal or subnormal doses)
Number of subjects: 36
Study: 31759466

Group type: EXPERIMENTAL
Intervention: CARE program
Number of subjects: 224

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 224
Study: 26585908

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 95
Study: 25887095

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ondansetron (4mg)
Number of subjects: 63
Study: 23348146

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg bid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21186977

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19057212

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection into the prostate
Number of subjects: 0
Study: 17724497

Group type: EXPERIMENTAL
Intervention: Dalbavancin (1 g followed by 500 mg one week later)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 1500
Study: 15492164

Group type: EXPERIMENTAL
Intervention: Cerumenex (10% triethanolamine polypeptide oleate‐condensate)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Murine (6.5% carbamide peroxide)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (BSS Sterile Irrigating Solution)
Number of subjects: 74
Study: 11710931

Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen (SPF 25, UVA protection factor 14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultraviolet B sunscreen (SPF 25, UVA protection factor 6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unprotected volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen (SPF 9, UVA protection factor 9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultraviolet B sunscreen (SPF 9, UVA protection factor 2)
Number of subjects: 0
Study: 9272806

Group type: EXPERIMENTAL
Intervention: Patients in congruent dyads (pain intensity scores matched with caregivers)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients in non-congruent dyads (pain intensity scores differed by >10 on VAS)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Family caregivers in congruent dyads
Number of subjects: 78

Group type: COMPARATOR
Intervention: Family caregivers in non-congruent dyads
Number of subjects: 78
Study: 7813167

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day for six months)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day for six months)
Number of subjects: 12
Study: 2684107

Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium, 3 x 2 g/d, intravenously (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Penicillin G, 4 x 5 million U/d (n = 10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cefotaxime and Penicillin G
Number of subjects: 21
Study: 1108695

Group type: EXPERIMENTAL
Intervention: 20 mg of cocaine dissolved in 2 ml of saline without adrenaline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 35 mg of cocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50 mg of cocaine
Number of subjects: 45
Study: 31359734

Group type: EXPERIMENTAL
Intervention: Fuyanshu Capsules combined with levofloxacin hydrochloride and metronidazole for 56 days and 14 days respectively
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group received Fuyanshu Capsules as its analogue
Number of subjects: 112
Study: 28689920

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 192
Study: 24849304

Group type: EXPERIMENTAL
Intervention: Home-based telemonitored cardiac rehabilitation (HTCR Group, n=75)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Outpatient-based standard cardiac rehabilitation (SCR Group, n=56)
Number of subjects: 131
Study: 23381958

Group type: EXPERIMENTAL
Intervention: ACT-178882 100 mg single dose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diltiazem 300 mg once a day for 13 days + ACT-178882 100 mg single dose on day 4
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of ACT-178882 alone vs. with diltiazem
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ACT-178882 alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ACT-178882 with diltiazem
Number of subjects: 14
Study: 21690070

Group type: EXPERIMENTAL
Intervention: 4% gelofusine solution at the rate of 20 ml/kg/h 30 min before the operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactated Ringers solution at 4 ml/kg/h for maintenance of total blood volume
Number of subjects: 40
Study: 19757979

Group type: EXPERIMENTAL
Intervention: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine) with TCM cold pattern
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine) with TCM hot pattern
Number of subjects: 194
Study: 17288327

Group type: EXPERIMENTAL
Intervention: AB2/SP (All Bond 2/Duolink with self-cure)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SOLO/SP (Optibond Solo Plus Dual Cure with self-cure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: AB2/LP (All Bond 2/Duolink with light cure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SOLO/LP (Optibond Solo Plus Dual Cure with light cure)
Number of subjects: 40
Study: 15069129

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Discectomy
Number of subjects: 100
Study: 11315891

Group type: EXPERIMENTAL
Intervention: 6.0 mm endoscope
Number of subjects: 322

Group type: COMPARATOR
Intervention: 9.8 mm endoscope
Number of subjects: 322
Study: 9398103

Group type: EXPERIMENTAL
Intervention: Digitalis (deslanoside 0.01 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7514506

Group type: EXPERIMENTAL
Intervention: Hydromorphone PCA (0.1 mg/hr basal infusion, 0.2 mg Q 5 min bolus, max 1.2 mg/hr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional analgesic therapy (CAT) with morphine 2.5 mg iv Q 30 min prn until extubation, followed by meperidine 1 mg/kg im Q 4 hr or acetaminophen 325 mg with codeine 30 mg po (1 or 2 tablets) when oral intake possible
Number of subjects: 0